| Literature DB >> 34367469 |
Rickta Rani Das1, Md Atiar Rahman1, Salahuddin Qader Al-Araby1, Md Shahidul Islam1, Md Mamunur Rashid1, Nouf Abubakr Babteen2, Afnan M Alnajeebi2, Hend Faisal H Alharbi3, Philippe Jeandet4, Md Khalid Juhani Rafi1, Tanvir Ahmed Siddique1, Md Nazim Uddin5, Zainul Amiruddin Zakaria6.
Abstract
The purpose of this study was to look into the effects of green coconut mesocarp juice extract (CMJE) on diabetes-related problems in streptozotocin- (STZ-) induced type 2 diabetes, as well as the antioxidative functions of its natural compounds in regulating the associated genes and biochemical markers. CMJE's antioxidative properties were evaluated by the standard antioxidant assays of 1,1-diphenyl-2-picrylhydrazyl (DPPH), superoxide radical, nitric oxide, and ferrous ions along with the total phenolic and flavonoids content. The α-amylase inhibitory effect was measured by an established method. The antidiabetic effect of CMJE was assayed by fructose-fed STZ-induced diabetic models in albino rats. The obtained results were verified by bioinformatics-based network pharmacological tools: STITCH, STRING, GSEA, and Cytoscape plugin cytoHubba bioinformatics tools. The results showed that GC-MS-characterized compounds from CMJE displayed a very promising antioxidative potential. In an animal model study, CMJE significantly (P < 0.05) decreased blood glucose, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, uric acid, and lipid levels and increased glucose tolerance as well as glucose homeostasis (HOMA-IR and HOMA-b scores). The animal's body weights and relative organ weights were found to be partially restored. Tissue architectures of the pancreas and the kidney were remarkably improved by low doses of CMJE. Compound-protein interactions showed that thymine, catechol, and 5-hydroxymethylfurfural of CMJE interacted with 84 target proteins. Of the top 15 proteins found by Cytoscape 3.6.1, 8, CAT and OGG1 (downregulated) and CASP3, COMT, CYP1B1, DPYD, NQO1, and PTGS1 (upregulated), were dysregulated in diabetes-related kidney disease. The data demonstrate the highly prospective use of CMJE in the regulation of tubulointerstitial tissues of patients with diabetic nephropathy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34367469 PMCID: PMC8337112 DOI: 10.1155/2021/9711176
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Total phenolic, total flavonoid, lycopene, and carotenoid contents of CMJE.
| Phytochemical index | Quantity |
|---|---|
| Total flavonoid | 80.0 mg rutin/g |
| Total phenolic content | 102.0 mg GAE/g |
| Lycopene | 0.031 mg/g |
| Total carotenoids | 0.058 mg/g |
Figure 1Effect of CMJE on scavenging capacities in DPPH (2,2-diphenyl 1-picrylhydrazyl) radical scavenging, SO (superoxide) scavenging, ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical scavenging, NO (nitric oxide) scavenging, and IC (iron-chelating) assays. All values were presented as means ± SD (triplicate). Data were analyzed by one-way ANOVA (analysis of variance) using the SPSS (Statistical Package for Social Science) software followed by Tukey's post hoc test.
Comparative IC50 values achieved by CMJE in different antioxidative models.
| Antioxidative models | Test sample | Reference standard | Inhibition concentration (IC50, | |
|---|---|---|---|---|
| CMJE | Reference standard | |||
| DPPH scavenging assay | CMJE | Ascorbic acid | 123.02 ± 6.42 | |
| Superoxide scavenging assay | CMJE | Ascorbic acid | 27.85 ± 1.32 | 16.21 ± 2.34 |
| Nitric oxide assay | CMJE | Ascorbic acid | 284.40 ± 5.05 | |
| Iron-chelating assay | CMJE | Ascorbic acid | 245.47 ± 4.34 | |
| ABTS assay | CMJE | Trolox | 386.36 ± 1.22 | 92.07 ± 3.21 |
Figure 2Effects of CMJE on the α-amylase inhibitory activity. Acarbose was used as the reference standard. Data are presented as means ± SD (triplicate). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (Statistical Package for Social Science, version 20.0) followed by Tukey's post hoc test. Superscript letters (a, b) over the graphical bars indicate the statistical difference between inhibitory effect of CMJE and acarbose.
Figure 3Effects of CMJE extracts on body weight (a) and weekly blood glucose levels (b) of treated animals. Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance). Significance was confirmed at P < 0.05. Alphabets (a–c) over the line graphs indicate the statistical differences among the groups.
Figure 4Effects of CMJE on oral glucose tolerance (OGT) at the third week of intervention. Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (Statistical Package for Social Science, version 20.0) followed by Tukey's post hoc test. Data significance was confirmed at P ≤ 0.05.
Effects of CMJE on the glucose homeostatic status (HOMA-IR and HOMA-β).
| Treatment groups | HOMA-IR (mIU/L) | HOMA- |
|---|---|---|
| NC | 0.017 | 0.460 |
| DC | 0.116 | 0.036 |
| CMJE50 | 0.052 | 0.240 |
| CMJE100 | 0.155 | 0.045 |
| CMJE200 | 0.111 | 0.082 |
HOMA-IR stands for homeostatic model assessment for insulin resistance, and HOMA-β represents the pancreatic beta cell function (%).
Effects of CMJE on the relative weight of the pancreas and kidney of treated animals.
| Tissue weight | Pancreas weight (g) | Kidney weight (g) |
|---|---|---|
| NC | 0.569 ± 0.105a | 1.794 ± 0.106a |
| DC | 0.304 ± 0.047b | 1.738 ± 0.093a |
| CMJE50 | 0.215 ± 0.044c | 1.772 ± 0.127a |
| CMJE100 | 0.320 ± 0.050b | 1.690 ± 0.031a |
| CMJE200 | 0.215 ± 0.035c | 1.663 ± 0.199a |
Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (Statistical Package for Social Science, version 20.0) followed by Tukey's post hoc test. Data significance was confirmed at P ≤ 0.05. The superscript alphabets (a–c) in the table denote the reciprocal significance between and among the groups.
Effects of CMJE on serum ALT, AST, uric acid and creatinine levels.
| Treatment groups | ALT (U/L) | AST (U/L) | Uric acid (mg/dL) | Creatinine (mg/dL) |
|---|---|---|---|---|
| NC | 71.60 ± 2.40a | 4.80 ± 1.76a | 6.60 ± 2.40a | 0.49 |
| DC | 33.75 ± 2.50b | 7.62 ± 2.00b | 12.00 ± 2.80b | 1.23 |
| CMJE50 | 73.5 0 ± 7.20a | 6.00 ± 1.2 0c | 6.30 ± 0.72a | 0.71 |
| CMJE100 | 80.00 ± 8.00a | 5.17 ± 1.04c | 6.59 ± 0.82a | 0.77 |
| CMJE200 | 79.00 ± 8.10a | 6.50 ± 0.85b | 7.18 ± 0.71c | 0.68 |
Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (IBM Corporation, NY, version 20.0) followed by Tukey's post hoc test for significance at P ≤ 0.05. The significant differences among and between the groups at least in the experimental condition are represented through the superscript letters (a–c) in the table.
Figure 5Effects of CMJE on serum cholesterol and triglyceride levels of treated animals. Data are expressed as means ± SD (n = 6). All data were analyzed by one-way ANOVA (analysis of variance) using the statistical software SPSS (Statistical Package for Social Science, version 20.0) followed by Tukey's post hoc test for significance at P ≤ 0.05. Superscript letters (a, b) on the bar graph represent the values that are significantly different compared to each other at least at the intervention period.
Effect of CMJE on the tissue architectures of the pancreas and kidney.
| Name of the tissues and parameters | Group | ||||
|---|---|---|---|---|---|
| NC | DC | CMJE50 | CMJE100 | CMJE200 | |
| Pancreas | |||||
| Degenerated cells | - | +++ | ++ | + | + |
| Necrotic cells | - | +++ | + | + | ++ |
| Kidney | |||||
| Atrophic glomerulus and tubules | - | ++ | - | - | - |
| Eosinophilic secretion in the tubules lumen | - | - | - | - | - |
| Tubular epithelial cell degeneration | - | +++ | - | ++ | ++ |
| Increased fibrous tissue | - | ++ | + | + | + |
| Hyperemic vessels in the interstitium | - | +++ | + | + | + |
Histopathological assessments are graded as follows: (i) (-) indicates “no abnormality.” (ii) (+) indicates “mild injury.” (iii) (++) indicates “moderate injury.” (iv) (+ + +) indicates “severe injury”.
Figure 6Histopathological examination by hematoxylin and eosin staining of pancreatic (a) and kidney (b) tissues after the intervention (microscopic resolution: 10 × 40). Light microscopies of pancreatic sections stained with PAS and counterstained with hematoxylin are shown. NC, DC, CMJE50, CMJE100, and CMJE200 stand for normal control (diabetic control, coconut mesocarp juice extract 50 mg/kg bw, coconut mesocarp juice extract 100 mg/kg bw, and coconut mesocarp juice extract 200 mg/kg bw).
Figure 7GC-MS spectra of CMJE obtained from the mass spectrometer-electron impact ionization (EI) method (GC-MS TQ 8040, Shimadzu Corporation, Kyoto, Japan) coupled with a gas chromatograph (GC-17A, Shimadzu Corporation, Kyoto, Japan). A fused silica capillary column with inlet temperature 260°C and oven temperature 70°C (0 min) was programmed. The mass range was set in the range of 50-550 m/z.
Compounds obtained from GC-MS analyses of the CMJE.
| SL No. | Compound name | RT | Peak area (%) |
|---|---|---|---|
| 1 | 3-Trans-methoxy-2-cis-methyl-1R-cyclohexanol | 3.53 | 1.27 |
| 2 | 2,4(1H, 3H)-Pyrimidinedione, dihydro | 3.625 | 1.58 |
| 3 | Butanoic acid, 2-(hydroxymethyl)-ethyl ester (R)- | 3.72 | 0.52 |
| 4 | 2-Methylbutanoic anhydride | 3.844 | 3.61 |
| 5 | Thymine | 3.994 | 7.1 |
| 6 | Methyl 2-furoate | 4.083 | 1.73 |
| 7 | Trimethylaluminum | 4.210 | 0.96 |
| 8 | Ethanamine, N-ethyl-N-nitroso- | 4.624 | 1.91 |
| 9 | 2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one | 4.751 | 12.94 |
| 10 | 3-(Methylthio)propanoic acid ethyl ester | 4.833 | 7.24 |
| 11 | (S)-5-Hydroxymethyl-2[5H]-furanone | 5.064 | 0.71 |
| 12 | 3,5-Dihydroxy-2-methyl-4H-pyran-4-one | 5.158 | 0.34 |
| 13 | Catechol | 5.253 | 7.20 |
| 14 | Butanedioic acid, 2-hydroxy-2-methyl-, dimethyl ester, (2R)- | 5.358 | 1.00 |
| 15 | 2H-pyran-2-methanol, tetrahydro- | 5.494 | 5.20 |
| 16. | 5-Hydroxymethylfurfural | 5.618 | 14.41 |
| 17 | Butanedioic acid, hydroxy-, dimethyl ester | 5.82 | 1.71 |
| 18 | Undecenyl tiglate, 10- | 6.291 | 1.07 |
| 19 | 1-(Methylthio)-3-pentanone | 6.353 | 1.86 |
| 20 | 3,4-Hexanediol, 2,5-dimethyl- | 6.49 | 1.26 |
| 21 | Fumaric acid, monoamide, N,N-dimethyl-, 2-ethylhexyl ester | 6.561 | 0.78 |
| 22 | Heptyl caprylate | 6.741 | 1.57 |
| 23 | Butanedioic acid, 2-hydroxy-2-methyl-, (S)- | 7.002 | 1.08 |
| 24 | Phenol, 4-propyl- | 7.364 | 1.58 |
| 25 | 1,2,3-Benzenetriol | 7.505 | 2.44 |
| 26 | Tetradecane | 7.674 | 1.20 |
| 27 | Benzene, 1-chloro-4-methoxy- | 7.75 | 0.42 |
| 28 | Butanamide, 2-hydroxy-N,2,3,3-tetramethyl- | 7.933 | 1.04 |
| 29 | 2-hydroxy-4-methyl-benzaldehyde | 8.23 | 3.70 |
| 30 | (Z),(Z)-2,5-Dimethyl-2,4-hexadienedioic acid | 8.808 | 1.34 |
| 31 | Pentadecane | 8.933 | 1.50 |
| 32 | Hexadecane | 10.168 | 1.04 |
| 33 | 1,3-Benzenediol, 4-propyl- | 10.273 | 0.81 |
| 34 | 3-Deoxy-d-mannoic lactone | 10.948 | 2.49 |
| 35 | Butanoic acid, 2-methyl-, hexyl ester | 11.150 | 0.40 |
| 36 | 3-Deoxy-d-mannonic acid | 11.213 | 0.95 |
| 37 | 2-Hydroxy-5-methylisophthalaldehyde | 12.658 | 0.87 |
Figure 8The protein-protein interaction (PPI) network of the 75 target proteins.
Gene Ontology (GO) enrichment analysis of the interacting target proteins; 43 biological processes, 15 molecular functions, and 2 cellular components.
| Category | Term | Benjamini-corrected |
|---|---|---|
| BP | GO:0042744, hydrogen peroxide catabolic process | 5.78 |
| GO:0098869, cellular oxidant detoxification | 1.08 | |
| GO:0055114, oxidation-reduction process | 6.90 | |
| GO:0050482, arachidonic acid secretion | 1.03 | |
| GO:0036149, phosphatidylinositol acyl-chain remodeling | 5.02 | |
| GO:0036148, phosphatidylglycerol acyl-chain remodeling | 9.64 | |
| GO:0036150, phosphatidylserine acyl-chain remodeling | 9.64 | |
| GO:0032355, response to estradiol | 1.53 | |
| GO:0036152, phosphatidylethanolamine acyl-chain remodeling | 5.14 | |
| GO:0006979, response to oxidative stress | 6.62 | |
| GO:0036151, phosphatidylcholine acyl-chain remodeling | 8.95 | |
| GO:0006654, phosphatidic acid biosynthetic process | 4.34 | |
| GO:0006805, xenobiotic metabolic process | 2.18 | |
| GO:0016042, lipid catabolic process | 3.67 | |
| GO:0046135, pyrimidine nucleoside catabolic process | 4.76 | |
| GO:0006644, phospholipid metabolic process | 4.76 | |
| GO:0045471, response to ethanol | 1.29 | |
| GO:0007568, aging | 1.91 | |
| GO:0008202, steroid metabolic process | 3.89 | |
| GO:0045008, depyrimidination | 1.48 | |
| GO:0042493, response to drug | 1.82 | |
| GO:0032496, response to lipopolysaccharide | 1.97 | |
| GO:0006584, catecholamine metabolic process | 1.91 | |
| GO:0046677, response to antibiotic | 2.95 | |
| GO:0051923, sulfation | 3.42 | |
| GO:0006284, base-excision repair | 3.92 | |
| GO:0050427, 3′-phosphoadenosine 5′-phosphosulfate metabolic process | 8.60 | |
| GO:0032025, response to cobalt ion | 6.80 | |
| GO:0009635, response to herbicide | 9.14 | |
| GO:0009636, response to toxic substance | 1.11 | |
| GO:0009308, amine metabolic process | 1.13 | |
| GO:0009812, flavonoid metabolic process | 1.13 | |
| GO:0008635, activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c | 1.40 | |
| GO:0043066, negative regulation of apoptotic process | 1.42 | |
| GO:0042416, dopamine biosynthetic process | 1.64 | |
| GO:0043525, positive regulation of neuron apoptotic process | 1.63 | |
| GO:0008210, estrogen metabolic process | 1.89 | |
| GO:0043097, pyrimidine nucleoside salvage | 2.19 | |
| GO:0042542, response to hydrogen peroxide | 2.45 | |
| GO:0071407, cellular response to organic cyclic compound | 3.62 | |
| GO:0097194, execution phase of apoptosis | 3.61 | |
| GO:0080111, DNA demethylation | 3.61 | |
| GO:0033189, response to vitamin A | 4.45 | |
| CC | GO:0005829, cytosol | 4.25 |
| GO:0005739, mitochondrion | 1.18 | |
| MF | GO:0004601, peroxidase activity | 5.24 |
| GO:0020037, heme binding | 5.97 | |
| GO:0004623, phospholipase A2 activity | 3.61 | |
| GO:0003684, damaged DNA binding | 1.60 | |
| GO:0005506, iron ion binding | 1.30 | |
| GO:0019825, oxygen binding | 6.41 | |
| GO:0004062, aryl sulfotransferase activity | 5.34 | |
| GO:0097153, cysteine-type endopeptidase activity involved in apoptotic process | 6.06 | |
| GO:0008146, sulfotransferase activity | 1.35 | |
| GO:0047498, calcium-dependent phospholipase A2 activity | 1.48 | |
| GO:0019104, DNA N-glycosylase activity | 1.67 | |
| GO:0030983, mismatched DNA binding | 1.87 | |
| GO:0016712, oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 3.23 | |
| GO:0004497, monooxygenase activity | 3.21 | |
| GO:0004197, cysteine-type endopeptidase activity | 3.46 |
Enriched KEGG pathways significantly associated with target proteins in this study.
| KEGG pathway | Benjamini-corrected |
|---|---|
| hsa00592: alpha-linolenic acid metabolism | 1.96 |
| hsa00590: arachidonic acid metabolism | 1.81 |
| hsa00591: linoleic acid metabolism | 2.06 |
| hsa04975: fat digestion and absorption | 1.42 |
| hsa00565: ether lipid metabolism | 3.21 |
| hsa01100: metabolic pathways | 5.47 |
| hsa04972: pancreatic secretion | 3.39 |
| hsa00564: glycerophospholipid metabolism | 3.42 |
| hsa05204: chemical carcinogenesis | 1.10 |
| hsa04270: vascular smooth muscle contraction | 1.05 |
| hsa03460: fanconi anemia pathway | 1.23 |
| hsa00140: steroid hormone biosynthesis | 1.74 |
| hsa00350: tyrosine metabolism | 2.51 |
| hsa00980: metabolism of xenobiotics by cytochrome P450 | 4.69 |
| hsa00983: drug metabolism—other enzymes | 6.29 |
| hsa00240: pyrimidine metabolism | 1.66 |
| hsa04210: apoptosis | 1.69 |
| hsa03410: base-excision repair | 2.19 |
| hsa04014: ras signaling pathway | 2.74 |
| hsa00380: tryptophan metabolism | 3.39 |
Figure 9Dysregulation of hub targets (mRNA expression levels) in diabetic human kidney tubuli, when compared with control tubuli. FC: fold change, DKDT: diabetic kidney disease tubuli, control: control tubuli, ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.